Company news

Humanwell Healthcare (Group) Co.,Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Announcement on Obtaining Drug Registration Certificate by Subsidiary

April 7, 2026

Announcement on Risk Assessment Report for China Merchants Group Finance Co., Ltd.

March 30, 2026

Announcement on Initiation of Phase II Clinical Trial for HW091077 Tablets

March 23, 2026

Announcement on Holding Subsidiary's Passing EU GMP Compliance Inspection

March 2, 2026

Announcement on Micafungin Sodium for Injection Obtaining US FDA Approval

February 27, 2026

Announcement on the Temporary Suspension of the Shareholders’ Meeting to Deliberate on the Issuance of A-shares to Specific Investors in 2026

February 24, 2026

Announcement on Progress in the Establishment of Private Equity Fund Investment and Related Party Transaction

January 30, 2026

Announcement on HW221043 Tablets Obtaining Notice of Approval for Drug Clinical Trials

January 5, 2026

Announcement on Receiving the Decision for Administrative Penalty from Hubei Securities Regulatory Bureau of China Securities Regulatory Commission

December 29, 2025

Announcement on Progress in Establishment in Private Equity Fund Investment and Related Party Transaction

December 24, 2025

Indicative Announcement on the Results of Controlling Shareholder's Share Increase and Equity Change Reaching 1% Scale

December 22, 2025

Announcement on HW252001 Tablets Obtaining Notice of Approval for Drug Clinical Trials

December 19, 2025

Announcement on Receiving the Notice in Advance of Administrative Penalty from Hubei Securities Regulatory Bureau of China Securities Regulatory Commission

December 12, 2025

Announcement on Obtaining Marketing Authorization from the German Federal Institute for Drugs and Medical Devices (BfArM) for Midazolam Injection

December 11, 2025

Announcement on Resolutions of the 4th Meeting of the 11th Board of Directors

December 5, 2025

Announcement on Withdrawal of Drug Registration Application by Subsidiary

December 2, 2025

Announcement on Participation in Investment for Establishing Private Equity Fund and Related Party Transaction

November 28, 2025

Announcement on Initiation of Phase II Clinical Trial for HW231019 Tablets

November 12, 2025

Announcement on Pledge of Partial Shares of Controlling Shareholder

November 7, 2025

Announcement on HWH217 Tablets Obtaining Notice of Approval for Drug Clinical Trials

November 6, 2025

Announcement on Pregabalin Sustained Release Tablets Obtaining Notice of Approval for Drug Clinical Trials

November 3, 2025

Announcement on the Fulfillment of Commitments by Shareholders Holding More Than 5% Shares

October 30, 2025

Announcement on Resolutions of the 3rd Meeting of the 11th Board of Directors

October 29, 2025

Announcement on Progress in Signing of "Financial Services Agreement" and Related Party Transactions

October 13, 2025

Announcement on Temporary Approval Number Granted by the US FDA for Oxcitabine Sustained-release Tablets

September 19, 2025

Announcement on Obtaining Drug Registration Certificate for Levonorgestrel Tablets

September 16, 2025

Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025

September 12, 2025

Announcement on Jade Silkworm Granules Entering Phase 2 Clinical Trial Study

September 9, 2025

Announcement on Obtaining Drug Registration Certificate for Icosapent Ethyl Soft Capsules

September 2, 2025

Indicative Announcement on Equity Change of Controlling Shareholder and Its Persons Acting in Concert Reaching 1%

September 1, 2025

Announcement on Renewing Engagement of Accounting Firm

August 27, 2025

Announcement on Obtaining Drug Registration Certificate for Remimazolam Besylate for Injection with Increased Indications

August 25, 2025

Announcement on Implementation of Dividend Distribution for 2024

August 11, 2025

Announcement on HW241045 Tablets Obtaining Notice of Approval for Drug Clinical Trials

August 5, 2025

Announcement on Approval of Drug Registration Certificate for Drospirenone and Ethinylestradiol Tablets

July 31, 2025

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

July 30, 2025

Announcement on Obtaining Drug Registration Certificate for Rivastigmine Transdermal Patch

July 22, 2025

Announcement on Adding Extraordinary Proposal to the 3rd Extraordinary General Meeting in 2025

July 18, 2025

Humanwell Healthcare (Group): >Humanwell PuraCap Pharmaceutical LLC Announces Successful FDA Inspection

November 11, 2015

← Newer news releases